IART vs. ATEC, ATRC, GMED, TNDM, ICUI, NARI, PRCT, LMAT, NVCR, and AXNX
Should you be buying Integra LifeSciences stock or one of its competitors? The main competitors of Integra LifeSciences include Alphatec (ATEC), AtriCure (ATRC), Globus Medical (GMED), Tandem Diabetes Care (TNDM), ICU Medical (ICUI), Inari Medical (NARI), PROCEPT BioRobotics (PRCT), LeMaitre Vascular (LMAT), NovoCure (NVCR), and Axonics (AXNX). These companies are all part of the "surgical & medical instruments" industry.
Alphatec (NASDAQ:ATEC) and Integra LifeSciences (NASDAQ:IART) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, community ranking, analyst recommendations, dividends, earnings, media sentiment and risk.
Integra LifeSciences received 123 more outperform votes than Alphatec when rated by MarketBeat users. Likewise, 58.31% of users gave Integra LifeSciences an outperform vote while only 56.52% of users gave Alphatec an outperform vote.
Alphatec presently has a consensus price target of $23.63, indicating a potential upside of 73.08%. Integra LifeSciences has a consensus price target of $44.89, indicating a potential upside of 55.38%. Given Integra LifeSciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Alphatec is more favorable than Integra LifeSciences.
Integra LifeSciences has higher revenue and earnings than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Integra LifeSciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Alphatec and Alphatec both had 6 articles in the media. Integra LifeSciences' average media sentiment score of 0.86 beat Alphatec's score of 0.12 indicating that Alphatec is being referred to more favorably in the media.
Alphatec has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Integra LifeSciences has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500.
66.4% of Alphatec shares are owned by institutional investors. Comparatively, 84.8% of Integra LifeSciences shares are owned by institutional investors. 29.1% of Alphatec shares are owned by insiders. Comparatively, 3.1% of Integra LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Integra LifeSciences has a net margin of 4.39% compared to Integra LifeSciences' net margin of -38.70%. Alphatec's return on equity of 15.19% beat Integra LifeSciences' return on equity.
Summary
Integra LifeSciences beats Alphatec on 10 of the 17 factors compared between the two stocks.
Get Integra LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for IART and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IART and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Integra LifeSciences Competitors List
Related Companies and Tools
